Page 2524 - Williams Hematology ( PDFDrive )

2495
2494 Index Index 2495

lymphomas/lymphoproliferative disorders. immunodeficiencies with impaired Temsirolimus, for mantle cell lymphoma,
See also Cutaneous T-cell NF-κB activation, 1220 1658, 1659t, 1660t. See also
lymphoma (CTCL); Peripheral Epstein-Barr virus-specific, 411–412 Mammalian target of rapamycin
T-cell lymphoma (PTCL) erythropoietic failure and, 543 (mTOR) inhibitors
chromosomal abnormalities, 185t fetal, 101 Tenascin, 63, 267
classification, 1493, 1498–1499t, in gene therapy, 438 Tenderness of the sternum, history of, 5
1598–1599 genetic retargeting, 414–416, 414f, Tenecteplase, 403
epidemiology, 1571 415f comparison to other fibrinolytics, 2313t
etiology, 1573 helper. See CD4+ T cells (helper T cells) for myocardial infarction, 2295
histologic subtypes, 1498–1499t, 1572t Hodgkin lymphoma and, 1607 for pulmonary embolism, 2277–2278
T-cell/NK cell progenitors, 270 immune modulatory molecules for stroke, 2315
T-cell precursors, 438 CD28, 415–416, 1183, 1184, 1185f Teniposide, 328–329
T-cell progenitors, 270 CD152 (CTLA-4), 424, 1184 adverse effects, 329, 1519t, 1520
T-cell prolymphocytic lymphoma (T-PLL), immunological synapse, 1185–1186 for α-heavy-chain disease, 1808
1498t, 1542 in immunologic response, 969 secondary acute myelogenous leukemia
T-cell receptor (TCR) genes, 414–415 leukemia-specific, 413–414 and, 183
T-cell receptor-interacting molecule 25 in lymph nodes, 92–93 TERC, 531, 531f
(TRIM25), 302, 302f melanoma-specific, 412–413 Terminal deoxynucleotidyl transferase (TdT),
T-cell receptors (TCRs), 1175–1177 memory. See Memory T cells 1465–1466
CD4. See CD4 multispecific, 412 Ternary complex formation, 825f, 826t,
CD8. See CD8 neonatal, 108 830–831, 830t
composition, 1177–1178 regulatory. See CD4+CD25+ regulatory TERT, 531, 531f
diversity in, 1177 T (T REG ) cells TERT (telomerase reverse transcriptase),
heterodimers, 1175–1176, 1176f in spleen, 91 1444–1445
antigen presentation to, 1177 suicide genes, 416 TERT/TERC, 1346t
gene rearrangements in, 1176–1177 tolerance in, 308 Testicular lymphoma, primary, 1246,
molecular features, 1178 T-cell therapy. See Immune cell therapy 1581–1582, 1582f, 1634
signaling defects, 1218, 1220 (adoptive cellular therapy) Testicular relapse, in acute lymphoblastic
signal transduction in, 1178–1179 TCF-1, 1156 leukemia, 1518
in thymus, 87 TCF3, 1672 Testosterone
T cells. See also Lymphocytes TCF3-PBX1 (E2A-PBX1), 1507, 1516 for anemia of primary myelofibrosis, 1328
adhesion molecules, 1184–1185, 1185f TCL1, 1529 erythropoietic response to, 872, 879–880, 880f
aging and, 135–136 TCRA, 1218 TET2
antigen receptors. See T-cell receptors TCRs. See T-cell receptors in acute myelogenous leukemia, 198, 226t,
antigens, 1141–1142, 1142f, 1142t TdT (terminal deoxynucleotidyl transferase), 1376, 1378–1379, 1378t
in atherosclerosis, 2286 1465–1466 in chronic myelomonocytic leukemia, 170,
autoreactive cytotoxic, in aplastic anemia, Teardrop cells. See Dacryocytes (teardrop 1468
515 cells) in myelodysplastic syndromes, 227t, 1346t,
CD4+. See CD4+ T cells (helper T cells) TEL (ETV6), 228t, 230, 1346t, 1351 1348, 1351
CD4+CD25+. See CD4+CD25+ regulatory TEL-AMI1. See ETV6-RUNX1 in peripheral T-cell lymphoma, 1697
T (T REG ) cells Telangiectasia macularis eruptiva perstans, in Ph-chromosome negative
CD8+. See CD8+ T cells (cytotoxic T 973 myeloproliferative neoplasms, 229t
lymphocytes, CTLs) Telangiectasias, 1988 in polycythemia vera, 1292
in chronic inflammation, 291 Telomerase reverse transcriptase (TERT), TET proteins, 169
commitment, regulation of, 1155–1156 1444–1445 Tetracyclines, 830
cytomegalovirus-specific, 409–411, 410f, Telomere defects Tetrahydrofolate acid (FH ), 584, 586f
4
411f in acute myelogenous leukemia, 1376 Tetrahydrofolate triglutamate, 584, 585f
cytotoxic. See CD8+ T cells (cytotoxic T in aplastic anemia, 515 Tetraspanins, 1858–1859t, 1871
lymphocytes, CTLs) in chronic myelogenous leukemia, Textarin/ecarin test, 2243
dendritic cells and, 308 1444–1445 TF. See Tissue factor (TF)
development, 86–87, 87f in dyskeratosis congenita, 530–531, T follicular helper (T ) cells, 1182
FH
disorders, 1195–1197, 1196–1197t. 531f TFPI. See Tissue factor pathway inhibitor (TFPI)
See also Cutaneous T-cell Temozolomide TFPI, 1937
lymphoma (CTCL); Peripheral for acute myelogenous leukemia, 1408 TfR2, 641, 642
T-cell lymphoma (PTCL); T-cell mechanism of action, 329 TGF. See under Transforming growth factor
neoplasms pharmacology, 330 (TGF)

Kaushansky_index_p2393-2506.indd 2495 9/21/15 3:22 PM